On April 29, 2020, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, reportedOpens in new window that data from an international clinical trial testing the broad-spectrum antiviral drug remdesivir in around 1,090 patients showed “quite good news” and should result in a new standard of care for COVID-19 patients.
Remdesivir was developed through an academic-corporate partnership between Gilead Sciences and the Baric Lab at the UNC Gillings School of Global Public HealthOpens in new window. The biopharmaceutical company sought the talents of a research team led by Ralph Baric,Opens in new window the William R. Kenan Jr. Distinguished Professor of Epidemiology, who has studied coronaviruses for more than 30 years and pioneered rapid-response approaches for the study of emerging viruses and the development of therapeutics.
“This is a game-changer for the treatment of patients with COVID-19,” Baric said upon hearing the results of the clinical trial. “Remdesivir provides an effective treatment strategy for the many infected individuals around the globe.”